Health Care Deal News, April 28, 2014 - Novartis AG Announced That it was Trading its Vaccine Business to GlaxoSmithKline plc, Private Equity Groups are Back in Action This Year, A Medical Device Company Announced the Completion of its Series B Financing

 

Brought to you by www.DealSearchOnline.com
 

April 28, 2014 Issue:

 

Recent Health Care M&A Deals

Laboratories, MRI and Dialysis

 

 

Acquirer

Target

Price

DaVita Kidney Care

Three hemodialysis centers

N/A

Medical Devices

 

 

Zimmer Holdings Inc.

Biomet, Inc.

$13.35 billion

NOVADAQ Technologies Inc.

Aimago SA

$10 million

Pharmaceuticals

 

 

Novartis Corporation

GlaxoSmithKline oncology business

$16 million

Endo International plc

Sumavel DosePro

$85 million

 

CIT knows healthcare

 

Technology Deal of the Week
Pharmaceutical deals made headlines last week, as Swiss drug maker Novartis AG (NYSE: NVS) announced on April 22 that it was trading its vaccine business to GlaxoSmithKline plc (NYSE: GSK) in exchange for GSK’s oncology drug business. Novartis agreed to pay $16 billion cash to GSK, of which $1.5 billion is contingent on the results of a Phase 3 trial. GSK agreed to pay Novartis $5.25 billion, plus up to $1.8 billion in milestones. Two other unsolicited deals went un-done, but it’s a lead-pipe cinch we’ll hear more about them. Pfizer (NYSE: PFE) reportedly made a $101 billion offer for AstraZeneca plc (NYSE: AZN), which was rebuffed, while serial acquirer Valeant Pharmaceuticals International (NYSE: VRX) made a $45 billion offer for Allergan, Inc. (NYSE: AGN). Allergan’s board immediately adopted a poison pill to ward off further advances, but this isn’t over.........Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.

 

Charted Territory
Private equity groups are back in action this year, in a big way. Through April 25, they’ve spent approximately $6.9 billion on 22 announced deals. This time last year, PE firms had spent only $654 million on 14 announced deals. Of course, this year’s total is boosted by the $4.15 billion deal from The Carlyle Group (NASDAQ: CG) for Johnson & Johnson’s (NYSE: JNJ) Ortho-Clinical Diagnostics division, but even without that deal, there’s still $2.7 billion on the table. Here are the top five acquisitions by PE firms, through April 22, 2014.

 

Top Five Health Care Deals by Private Equity Groups, Jan. – April, 2014        
 

Acquirer

Target

Price

The Carlyle Group

Ortho-Clinical Diagnostics, Inc.

$4.15 billion

Cinven

Medpace, Inc.

$915 million

Montagu Private Equity

Rexam plc’s healthcare units

$805 million

Buyer consortium

Chindex International, Inc.

$461 million

Kayne Anderson Real Estate

Conservatory Senior Living portfolio

$290 million

Source: The Health Care M&A News, April 2014

Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today

 

Services Deal of the Week
The services sector was fairly quiet last week, as all the hoopla went on around the technology space. Still, DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. (NYSE: DVA) announced it had acquired three hemodialysis centers from Malaysian dialysis provider Sinar Indentiti Sbn Bhd. Terms were not disclosed. The acquisition brings DaVita’s presence to 24 clinics across peninsular and east Malaysia. Kidney disease is a growing health concern, as the Malaysian Society of Nephrology reports the population of patients receiving dialysis treatment has grown nearly 12% year-over-year, to 30,000.......Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.

 

In the Pipeline
A medical device company announced the completion of its Series B financing last week, which is notable because medical device startups are having a hard time getting angel investors to take notice. Guardant Health of Redwood City, California closed its Series B round with more than $30 million, to support the continued commercial expansion of its Guardant360 non-invasive tumor sequencing test. The round was led by Khosla Ventures, which was joined by Sequoia Capital and new investor Pejman Mar Ventures......Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.

 

BioTrinity 2014 – European Biopartnering and Investment Conference, May 12-14, London, UK

Join 1000+ delegates from 30 countries at Europe’s Premier Biopartnering and Investment Conference: BioTrinity 2014. BioTrinity 2014 brings together R&D companies and Global Pharma organisations with more biomedical investors than any other European partnering conference.


To find out more about BioTrinity, or to register, please visit: www.biotrinity.com

 

 

NEW - The Health Care Services Acquisition Report, 20th Edition - Order Today!

Deals have been made. The 2014 Health Care Services Acquisition Report contains private deals in this market that are frequently too small to make into financial press. Order by April 30th and get our Senior Care M&A Market Review and 2014 Outlook webcast for FREE ($147 value). Now that’s a deal! Go to http://www.levinassociates.com/landing/har20order or call 800-248-1668 to preorder today.

 

 

Around the Web in Health Care M&A...Click here to see more

 
Webcast Calendar...Click here to see more

 

Upcoming Conference Partnerships... Click here to see more